Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 May 2025 | Story Leonie Bolleurs | Photo Supplied
Ruhan Fourie
Dr Ruhan Fourie, former postdoctoral fellow in the UFS International Studies Group and current researcher at Stellenbosch University’s Beyers Naudé Centre for Public Theology, was recently awarded the prestigious Desmond Tutu-Gerrit Brand Prize.

Dr Ruhan Fourie, a former fellow of the International Studies Group (ISG) at the University of the Free State (UFS), recently received the prestigious Desmond Tutu-Gerrit Brand Prize for Debut Work for his book, Christian Nationalism and Anticommunism in Twentieth Century South Africa (Routledge, published in South Africa by Christian Literature Fund).

A media release by the Andrew Murray-Desmond Tutu Prize Fund stated that the prizes primarily serve as motivation and recognition for writers to produce quality publications of theological and Christian work in all official languages of our country. The awards are given in recognition of extraordinary contributions to unity, reconciliation, and environmental justice in our country.

Currently a postdoctoral fellow in the Beyers Naudé Centre for Public Theology at the Stellenbosch University Faculty of Theology, Dr Fourie says the award is especially meaningful because of the book’s academic tone. “I hold public accessibility to scholarly work dear; so, to receive this recognition for a more scholarly work outside academia is very encouraging. When I got the call that I’d won the prize, it was met with great surprise and joy,” he says.

 

Challenging Cold War assumptions

In the book, he explores the deep-rooted fears that Afrikaners held about communism during the twentieth century. These fears are often assumed to be Cold War products, primarily shaped by the apartheid state. However, Dr Fourie’s research, undertaken as part of his postdoctoral fellowship in the UFS International Studies Group, challenges this simplified narrative. He approached anticommunism more broadly than merely opposition to the state-centred communist doctrine by focusing on the Dutch Reformed Church (DRC), which had the widest reach and deepest influence in the everyday lives of Afrikaners.

The book argues that while the DRC played a constant role in shaping an anti-communist imagination among twentieth-century Afrikaners, its influence shifted over time. “It ultimately concludes that anticommunism functioned as a vehicle for nationalist unity (and uniformity), a paradigm for Afrikaner identity, and a legitimiser of the volk’s perceptions of its imagined moral high ground throughout the twentieth century,” he notes.

Dr Fourie credits his time as a postdoctoral fellow (2022-2023) in the UFS ISG as a key part of developing his book. He describes the ISG as a place offering strong institutional support, valuable mentorship, and the academic freedom he needed to shape his ideas into a full monograph. As part of a research-led, student-centred, and regionally engaged institution such as the UFS – which is committed to development and serves as a hub of impactful knowledge – Dr Fourie found the right space to grow both his research and his contribution to the field of South African history.

 

Impact of UFS' academic environment

He spent a significant part of his emerging academic journey at the UFS. Besides the time he spent on his postdoctoral fellowship at the ISG, he also completed his PhD between 2018 and 2021 – marking a total association of six years with the university. “The ISG’s culture of scholarly rigour, academic freedom, mentorship, and institutional support under the guidance of Prof Ian Phimister, paired with collegiality and collaboration among peers, left a formative impression on me as an aspiring academic,” he comments.

Looking ahead, Dr Fourie is currently working on a project – a biography of anti-apartheid cleric Beyers Naudé. While based on solid academic research, the biography is being written for a wider audience and is aimed at trade publication, an approach that will bring Naudé’s life and legacy to both scholarly and general readers. His interest in Naudé runs deep; his master’s thesis on Naudé’s life was awarded a prize for the best Afrikaans thesis, an early indicator of the path his academic work would follow.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept